The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+cells with cancer stem cell characteristics
Open accessAbstract
Introduction: Whether cancer stem cells occur in BRCA1-associated breast cancer and contribute to therapeutic response is not known. Methods: We generated and characterized 16 cell lines from five distinct Brca1deficient mouse mammary tumors with respect to their cancer stem cell characteristics. Results: All cell lines derived from one tumor included increased numbers of CD44+/CD24- cells, which were previously identified as human breast cancer stem cells. All cell lines derived from another mammary tumor exhibited low levels of CD44+/CD24- cells, but they harbored 2% to 5.9% CD133+ cells, which were previously associated with cancer stem cells in other human and murine tumors. When plated in the absence of attachment without presorting, only those cell lines that were enriched in either stem cell marker formed spheroids, which were further enriched in cells expressing the respective cancer stem cell marker. In contrast, cells sorted for CD44+/CD24- or CD133+ markers lost their stem cell phenotype when cultured in monolayers. As few as 50 to 100 CD44+/CD24- or CD133+ sorted cells rapidly formed tumors in nonobese diabetic/severe combined immunodeficient mice, whereas 50-fold to 100-fold higher numbers of parental or stem cell depleted cells were required to form few, slow-growing tumors. Expression of stem cell associated genes, including Oct4, Notch1, Aldh1, Fgfr1, and Sox1, was increased in CD44+/CD24- and CD133+ cells. In addition, cells sorted for cancer stem cell markers and spheroid-forming cells were significantly more resistant to DNA-damaging drugs than were parental or stem cell depleted populations, and they were sensitized to the drugs by the heat shock protein-90 inhibitor 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride). Conclusion: Brca1-deficient mouse mammary tumors harbor heterogeneous cancer stem cell populations, and CD44+/CD24- cells represent a population that correlates with human breast cancer stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“However, reduced BRCA1 protein expression is detected in highgrade sporadic breast and ovarian tumors, suggesting that epigenetic downregulation of BRCA1 contributes to their aggressive clinical course [6-8].”
BackgroundBRCA1 Mutations in Primary Breast and Ovarian Carcinomas
Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., et al. (1994) · Science · doi:10.1126/science.7939630 · Cited by 1,205
Geran, R. I., Greenberg, N. H., MacDonald, M., Schumacher, A., & Abbott, B. J. (1972) · Cancer chemotherapy reports. Part 1 · Cited by 1,128
The origin of the cancer stem cell: current controversies and new insights
Bjerkvig, R., Tysnes, B. B., Aboody, K. S., Najbauer, J., & Terzis, A. J. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1740 · Cited by 595
Cited by
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
The epigenetics of epithelial-mesenchymal plasticity in cancer
Tam, W. L., & Weinberg, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3336 · Cited by 1,163
Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,158
Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D., & Eccles, S. A. (2012) · BMC Biology · doi:10.1186/1741-7007-10-29 · Cited by 1,024
Kao, J., Salari, K., Bocanegra, M., Choi, Y.-L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006146 · Cited by 788
Chiou, S.-H., Yu, C.-C., Huang, C.-Y., Lin, S.-C., Liu, C.-J., Tsai, T.-H., Chou, S.-H., Chien, C.-S., Ku, H.-H., & Lo, J.-F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4404 · Cited by 641
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Yu, F., Li, J., Chen, H., Fu, J., Ray, S., Huang, S., Zheng, H., & Ai, W. (2011) · Oncogene · doi:10.1038/onc.2010.591 · Cited by 473
Godar, S., Ince, T. A., Bell, G. W., Feldser, D., Donaher, J. L., Bergh, J., Liu, A., Miu, K., Watnick, R. S., Reinhardt, F., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.006 · Cited by 456
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
Baba, T., Convery, P. A., Matsumura, N., Whitaker, R. S., Kondoh, E., Perry, T., Huang, Z., Bentley, R. C., Mori, S., Fujii, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.374 · Cited by 419
Park, S. Y., Lee, H. E., Li, H., Shipitsin, M., Gelman, R., & Polyak, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1532 · Cited by 400
Cancer stem cell markers in common cancers – therapeutic implications
Klonisch, T., Wiechec, E., Hombach-Klonisch, S., Ande, S. R., Wesselborg, S., Schulze-Osthoff, K., & Los, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.08.003 · Cited by 393
Lee, C. J., Dosch, J., & Simeone, D. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6702 · Cited by 374
Targeting Breast Cancer Stem Cells
Liu, S., & Wicha, M. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 356
Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer
Bae, T., Hallis, S. P., & Kwak, M.-K. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01180-8 · Cited by 354
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche
Lock, F. E., McDonald, P. C., Lou, Y., Serrano, I., Chafe, S. C., Ostlund, C., Aparicio, S., Winum, J.-Y., Supuran, C. T., & Dedhar, S. (2013) · Oncogene · doi:10.1038/onc.2012.550 · Cited by 348
Cancer stem cell in breast cancer therapeutic resistance
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.004 · Cited by 328
Vaillant, F., Asselin-Labat, M.-L., Shackleton, M., Forrest, N. C., Lindeman, G. J., & Visvader, J. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1949 · Cited by 314
Rao, W., Wang, H., Han, J., Zhao, S., Dumbleton, J., Agarwal, P., Zhang, W., Zhao, G., Yu, J., Zynger, D. L., et al. (2015) · ACS Nano · doi:10.1021/nn506928p · Cited by 281
Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
Calcagno, A. M., Salcido, C. D., Gillet, J.-P., Wu, C.-P., Fostel, J. M., Mumau, M. D., Gottesman, M. M., Varticovski, L., & Ambudkar, S. V. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq361 · Cited by 279
Self-citationLiu, T. J., Sun, B. C., Zhao, X. L., Zhao, X. M., Sun, T., Gu, Q., Yao, Z., Dong, X. Y., Zhao, N., & Liu, N. (2013) · Oncogene · doi:10.1038/onc.2012.85 · Cited by 269
Mohammed, M. K., Shao, C., Wang, J., Wei, Q., Wang, X., Collier, Z., Tang, S., Liu, H., Zhang, F., Huang, J., et al. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2015.12.004 · Cited by 259
The multicellular tumor spheroid model for high-throughput cancer drug discovery
LaBarbera, D. V., Reid, B. G., & Yoo, B. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708334 · Cited by 255
Mandal, C. C., Ghosh-Choudhury, N., Yoneda, T., Choudhury, G. G., & Ghosh-Choudhury, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193714 · Cited by 138
Localization of CD44 and CD90 positive cells to the invasive front of breast tumors
Donnenberg, V. S., Donnenberg, A. D., Zimmerlin, L., Landreneau, R. J., Bhargava, R., Wetzel, R. A., Basse, P., & Brufsky, A. M. (2010) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20530 · Cited by 62
High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia
Pelissier Vatter, F. A., Schapiro, D., Chang, H., Borowsky, A. D., Lee, J. K., Parvin, B., Stampfer, M. R., LaBarge, M. A., Bodenmiller, B., & Lorens, J. B. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.114 · Cited by 58
Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors
Lara, H., Wang, Y., Beltran, A. S., Juárez-Moreno, K., Yuan, X., Kato, S., Leisewitz, A. V., Cuello Fredes, M., Licea, A. F., Connolly, D. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.360768 · Cited by 42
Valcz, G., Buzás, E. I., Szállási, Z., Kalmár, A., Krenács, T., Tulassay, Z., Igaz, P., & Molnár, B. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0071-9 · Cited by 27
Metadata
- Authors
- Wright, M. H., Calcagno, A. M., Salcido, C. D., Carlson, M. D., Ambudkar, S. V., & Varticovski, L.
- Venue
- Breast Cancer Research
- Published
- 2008-02-01
- Volume
- 10
- Issue
- 1
- Pages
- R10-R10
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1997280228
- Cited by
- 642
- References
- 42
- FWCI
- 29.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.